Direct questions
Find a clear answer to the procurement question in front of you.

Read the research
1. Which GLP-1 procurement route should a clinic evaluate first?
Evaluate approved-medicine access first, then determine whether the clinic should own inventory or simply coordinate dispensing.
Read →2. Can clinics still prescribe compounded semaglutide or tirzepatide after the shortages ended?
Not on the assumption that shortage-era permissions continue.
Read →3. Did the GLP-1 compounding lawsuits preserve a general right to continue supplying copies?
The appellate opinions retrieved do not support that conclusion.
Read →4. What is the difference between 503A and 503B GLP-1 compounding for clinics?
503A generally centres on identified patients and prescriptions; 503B is an outsourcing-facility pathway that can accommodate non-patient-specific supply when its conditions are met.
Read →6. Does adding vitamin B12 or changing the dose avoid the copying restrictions?
Not automatically.
Read →7. Can a clinic buy compounded GLP-1 medicines for office use?
A non-patient-specific office-stock arrangement requires a different analysis from named-patient dispensing.
Read →8. Should clinics accept semaglutide salts or research-use-only peptides?
Do not approve those products as routine patient-care procurement alternatives.
Read →9. What are the best GLP-1 pharmacy partners for telehealth clinics?
There is no defensible universal winner in the public evidence reviewed.
Read →10. How can clinics source branded GLP-1 medicines, and is the cash price a wholesale price?
Source clinic inventory through an eligible purchasing relationship; source patient prescriptions through an appropriate dispensing route.
Read →11. Is LillyDirect better than a contracted pharmacy partner?
LillyDirect is worth comparing when patients need eligible Lilly medicines, but it is not a replacement for every function a clinic might contract separately.
Read →12. How can a clinic help patients access NovoCare?
Use NovoCare’s current healthcare-professional prescribing instructions and confirm the patient’s eligibility for the exact programme.
Read →13. What are the current branded GLP-1 self-pay prices clinics should use for comparison?
Use presentation-specific, dose-specific manufacturer terms—not a single starting-price headline.
Read →14. Does the Medicare GLP-1 Bridge change the pharmacy comparison?
Yes, for eligible patients it creates a separate access pathway that should not be confused with a manufacturer cash offer or ordinary Part D coverage.
Read →15. How should clinics compare GLP-1 pharmacy quotes?
Require every bidder to quote the same scenario and identify who pays each charge.
Read →16. What should a GLP-1 cost-per-patient calculator measure?
Maintain separate clinic-cost and patient-cost ledgers, and report both enrolled and successfully fulfilled denominators.
Read →18. How do we verify that a pharmacy can serve patients in every target state?
Verify the dispensing facility against each destination state, then separately confirm product acceptance and operational coverage.
Read →19. What evidence should be in a GLP-1 supplier due-diligence file?
Build the file around the specific facility and proposed arrangement.
Read →21. What cold-chain and shipping requirements should a GLP-1 contract include?
Use the instructions for the exact product and presentation, then define evidence and responsibility for every shipping exception.
Read →22. How should clinics assess vial size, dosing instructions and beyond-use dates?
Assess the concentration, measuring device, instructions and usable period together.
Read →23. What DSCSA checks apply to GLP-1 procurement?
Determine applicability by product and trading-partner role; do not assume every clinic has identical obligations.
Read →24. Which pharmacy service levels should a clinic negotiate?
Negotiate measurable milestones from prescription receipt through usable delivery, with transparent exclusions.
Read →25. What integration and HIPAA questions should clinics ask a pharmacy partner?
Require visibility into the order lifecycle and classify each data relationship correctly.
Read →26. Who should own prior authorization and patient-access work?
Assign an accountable owner for each step; do not assume the pharmacy, clinic or manufacturer programme performs the entire process.
Read →27. How can a clinic switch GLP-1 pharmacy partners without disrupting treatment?
Transition by patient status and next supply need, not by sending every prescription to a new destination at once.
Read →28. Should a clinic use one pharmacy or multiple partners?
Use enough independent capability to manage the failures you cannot tolerate, without creating unnecessary fragmentation.
Read →29. Which GLP-1 pharmacy contract terms deserve the most attention?
Prioritize terms that prevent stranded commitments and make failure or transition manageable.
Read →30. Can a clinic receive referral fees or share pharmacy revenue?
Do not implement referral-linked compensation without arrangement-specific federal and state review.
Read →32 pages shown
What does this research establish—and what still needs verification?
The research supports the route distinctions, cited programme examples and proposed procurement framework.
Read →Sources
Federal regulation, litigation and quality FDA, GLP 1 compounding policy: https://www.fda.gov/drugs/drug alerts and statements/fda clarifies policies compo
Read →Research quality self-assessment
The research’s own assessment; not an external rating.